Earnings Summary

Inhibrx Inc’s revenue jumped 496.35% since last year same period to $1.63Mn in the Q4 2023. On a quarterly growth basis, Inhibrx Inc has generated 1273.11% jump in its revenue since last 3-months.

Inhibrx Inc’s net profit fell -128.78% since last year same period to $-93.6Mn in the Q4 2023. On a quarterly growth basis, Inhibrx Inc has generated -80.74% fall in its net profits since last 3-months.

Inhibrx Inc’s net profit margin jumped 61.64% since last year same period to -5728.52% in the Q4 2023. On a quarterly growth basis, Inhibrx Inc has generated 86.84% jump in its net profit margins since last 3-months.

Inhibrx Inc’s earning per share (EPS) estimates for the current quarter stand at -1.04 - a 0% jump from last quarter’s estimates.

Inhibrx Inc’s earning per share (EPS) estimates for the current year stand at -1.04.

Inhibrx Inc’s earning per share (EPS) fell -82.11% since last year same period to -1.73 in the Q4 2023. This indicates that the Inhibrx Inc has generated -82.11% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Inhibrx Inc’s return on assets (ROA) stands at -0.46.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Inhibrx Inc’s return on equity (ROE) stands at -4.75.